For example, tumor-infiltrating T cells surge when BRAF inhibitors and anti-PD1 antibodies are combined, prolonging survival and slowing tumor growth [157], as revealed by a BRAFV600E/PTEN-/- syngeneic tumor graft immunocompetent mouse model. Here, BRAF is linked to neoplasm.